MXPA05004058A - Proceso para la preparacion de (s,s)-cis-2benzhidril-3-bencilaminoquinuclidina. - Google Patents

Proceso para la preparacion de (s,s)-cis-2benzhidril-3-bencilaminoquinuclidina.

Info

Publication number
MXPA05004058A
MXPA05004058A MXPA05004058A MXPA05004058A MXPA05004058A MX PA05004058 A MXPA05004058 A MX PA05004058A MX PA05004058 A MXPA05004058 A MX PA05004058A MX PA05004058 A MXPA05004058 A MX PA05004058A MX PA05004058 A MXPA05004058 A MX PA05004058A
Authority
MX
Mexico
Prior art keywords
process according
further characterized
acid
salt
organic
Prior art date
Application number
MXPA05004058A
Other languages
English (en)
Spanish (es)
Inventor
Robert Seemayer
Original Assignee
Dsm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Pharmaceuticals Inc filed Critical Dsm Pharmaceuticals Inc
Publication of MXPA05004058A publication Critical patent/MXPA05004058A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05004058A 2002-10-16 2003-10-10 Proceso para la preparacion de (s,s)-cis-2benzhidril-3-bencilaminoquinuclidina. MXPA05004058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16
PCT/US2003/032275 WO2004035575A1 (en) 2002-10-16 2003-10-10 Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine

Publications (1)

Publication Number Publication Date
MXPA05004058A true MXPA05004058A (es) 2005-06-08

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004058A MXPA05004058A (es) 2002-10-16 2003-10-10 Proceso para la preparacion de (s,s)-cis-2benzhidril-3-bencilaminoquinuclidina.

Country Status (21)

Country Link
US (2) US6861526B2 (enExample)
EP (1) EP1551833A4 (enExample)
JP (1) JP2006506368A (enExample)
KR (1) KR100739901B1 (enExample)
CN (1) CN100418964C (enExample)
AP (1) AP2005003288A0 (enExample)
AR (1) AR041587A1 (enExample)
AU (1) AU2003277353B2 (enExample)
BR (1) BR0315335A (enExample)
CA (1) CA2500635A1 (enExample)
EA (1) EA008192B1 (enExample)
HR (1) HRP20050328A2 (enExample)
IS (1) IS7755A (enExample)
MX (1) MXPA05004058A (enExample)
PA (1) PA8586601A1 (enExample)
PE (1) PE20040777A1 (enExample)
PL (1) PL376218A1 (enExample)
TN (1) TNSN05111A1 (enExample)
UY (1) UY28024A1 (enExample)
WO (1) WO2004035575A1 (enExample)
ZA (1) ZA200502411B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1713504B1 (en) * 2004-01-30 2017-06-07 Zoetis Services LLC Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
ES2296131T3 (es) * 2004-02-02 2008-04-16 Pfizer Products Incorporated Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina.
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
PL170513B1 (en) 1991-05-22 1996-12-31 Pfizer Method of obtaining novel derivatives of 3-amino quinuclidine
WO1992021677A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. bibNUCLIDINE DERIVATIVES
EP1114823A3 (en) 1992-08-19 2001-07-18 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Also Published As

Publication number Publication date
CA2500635A1 (en) 2004-04-29
PE20040777A1 (es) 2004-11-20
AR041587A1 (es) 2005-05-26
US20050085641A1 (en) 2005-04-21
US20040116704A1 (en) 2004-06-17
IS7755A (is) 2005-03-17
CN1705664A (zh) 2005-12-07
PA8586601A1 (es) 2005-02-04
UY28024A1 (es) 2004-05-31
HRP20050328A2 (en) 2005-06-30
AU2003277353B2 (en) 2007-08-09
BR0315335A (pt) 2005-08-16
KR20050083764A (ko) 2005-08-26
WO2004035575A1 (en) 2004-04-29
TNSN05111A1 (en) 2007-05-14
KR100739901B1 (ko) 2007-07-13
HK1078087A1 (en) 2006-03-03
EA008192B1 (ru) 2007-04-27
AP2005003288A0 (en) 2005-06-30
US6861526B2 (en) 2005-03-01
JP2006506368A (ja) 2006-02-23
EP1551833A1 (en) 2005-07-13
EP1551833A4 (en) 2010-06-02
PL376218A1 (en) 2005-12-27
EA200500650A1 (ru) 2005-10-27
CN100418964C (zh) 2008-09-17
ZA200502411B (en) 2006-05-31
WO2004035575A8 (en) 2005-05-12
AU2003277353A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
US6861526B2 (en) Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
EP3956292B1 (en) A process for the preparation of enantiomerically pure norepinephrine
JPH11505229A (ja) 4−アリール−ピペリジン誘導体を製造する方法
HU216629B (hu) Eljárás 1-aza-biciklo[2.2.2]okt-3-il származékok előállítására
JP2007519710A (ja) 1−(2S,3S)−2−ベンズヒドリル−N−(5−tert−ブチル−2−メトキシベンジル)キヌクリジン−3−アミンの製造方法
JP5822880B2 (ja) (7s)−1−(3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル)n−メチルメタンアミンの酵素的合成方法、並びにイバブラジン及びその塩の合成における適用
KR0175933B1 (ko) 피소스티그민의 제조시 중간체로서 사용된 알킬화 옥신돌의 에난티오 선택적 합성 방법
US5521320A (en) Process for the enantioselective synthesis of intermediates used in the preparation of physostigmine
US6444822B1 (en) Process for the preparation of 3-substituted 4-phenyl-piperidine derivative
WO2002053537A1 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
CZ20011465A3 (cs) Způsob přípravy 4-arylpiperidin-3-methanolů a příbuzných sloučenin
HK1078087B (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine
CN1989097A (zh) 用于制备非对映异构体富集的化合物的方法
CN1295555A (zh) Hpb酯类化合物的制备方法
JP4529419B2 (ja) 光学活性含フッ素化合物類、及びこれらの製造方法
AU2001226773A1 (en) Process for preparing (plus or minus) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine

Legal Events

Date Code Title Description
FG Grant or registration